Apellis appoints Craig A. Wheeler to Board, effective April 17, 2025

Apellis Pharmaceuticals, Inc.

Craig A. Wheeler elected as Class III director; will serve until 2026 annual meeting.
Appointed to Audit Committee effective May 1, 2025; determined independent under Nasdaq rules.
Received option for 28,195 shares at $18.20 (3-year vest) and 16,483 RSUs (1-year vest).
Wheeler is former CEO of Momenta Pharmaceuticals (acquired by J&J) and current CEO of Headwaters Biotech Advisors.
No arrangements or family relationships with existing directors or executive officers.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Craig A. Wheeler

Director

APLS · Apellis Pharmaceuticals, Inc.

Effective: 2025-04-17
Filed: April 21, 2025, 7:59 PM ET

On April 17, 2025, the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), elected Craig A. Wheeler to the Board as a Class III director to serve until the Annual Meeting of Stockholders to be held in 2026 or until his successor has been duly elected and qualified or until his earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Craig A. Wheeler was elected as Director at Apellis Pharmaceuticals, Inc..

Action: elected
Role: Director

Exact text from the filing

On April 17, 2025, the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), elected Craig A. Wheeler to the Board as a Class III director to serve until the Annual Meeting of Stockholders to be held in 2026 or until his successor has been duly elected and qualified or until his earlier death, resignation or removal.

View on SEC.gov

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-086304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.